Results for all causality data translation from English to Slovak

the exposure-adjusted rates of rash (all causality) were 10.9,
expozícii prispôsobené miery vyrážky (všetky príčiny) boli 10,9, 4,2 resp.

all-causality bradycardia was reported in clinical studies in 13% of patients treated with crizotinib.
v klinických štúdiách sa u 13 % pacientov liečených krizotinibom hlásila bradykardia z akejkoľvek príčiny.

all-causality complex renal cysts were experienced by 52 (3%) of 1722 patients treated with crizotinib.
komplexné obličkové cysty z akejkoľvej príčiny uvádzalo 52 (3 %) z 1 722 pacientov liečených krizotinibom.

all-causality neuropathy, as defined in table 3, was experienced by 435 (25%) out of 1722 patients treated with crizotinib.
neuropatia z akejkoľvek príčiny, tak ako je definovaná v tabuľke 3, sa vyskytla u 435 (25 %) z 1 722 pacientov liečených krizotinibom.

importantly, the incidence of all-causality adverse events related to coronary artery disease, such as angina pectoris or myocardial infarction was not increased with the use of exubera.
dôležité je to, že incidencia nežiaducich účinkov akejkoľvek príčiny súvisiacich s ischemickou chorobou srdca, ako sú angina pectoris alebo infarkt myokardu, sa použitím exubery nezvýšila.

in studies with crizotinib in patients with either alk-positive or ros1-positive advanced nsclc, all-causality bradycardia was experienced by 219 (13%) of 1722 patients treated with crizotinib.
v štúdiách s krizotinibom u pacientov buď s alk-pozitívnym, alebo s ros1-pozitívnym pokročilým nsclc sa bradykardia z akejkoľvek príčiny objavila u 219 (13 %) z 1 722 pacientov liečených krizotinibom.

in the table below, since the majority of the studies were of an open nature all causality adverse events, by system organ class and frequency (very common ≥ 1/ 10, common ≥ 1/ 100 and < 1/ 10, uncommon ≥ 1/ 1000 and < 1/ 100, rare, ≥ 1/ 10 000 and < 1/ 1000 and very rare, < 1/ 10 000) if possibly causally related are listed.
v rámci